medigraphic.com
ISSN 1561-3070 (Electronic)

2020, Number 4

<< Back Next >>

Rev Cub Oftal 2020; 33 (4)

Effectiveness of dorzolamide in the treatment of cystoid macular edema after cataract surgery

Perera ME, Ramos LM, García FL, Hernández MR, Hernández SJR

Language: Spanish
References: 21
Page: 1-20
PDF size: 473.06 Kb.


ABSTRACT

Objective: Evaluate the effectiveness of a treatment combined with topical dorzolamide in patients with cystoid macular edema after cataract surgery.
Methods: An experimental study was conducted of patients attending the Vitreous-Retina Service at Ramón Pando Ferrer Cuban Institute of Ophthalmology in the year 2018. The sample was divided into a case group (dorzolamide and conventional treatment) and a control group (conventional treatment), and evaluated at the initial consultation and after one month of treatment.
Results: Mean age was 60.73 ± 11.25 years. A predominance was found of the female sex (53.33%), affected right eye (60.00%), postsurgical time ≤ 3 months (63.33%), and no associated risk factors (56.67%). Edema without associated alterations was more common (80.00%). Mean macular thickness decreased in both groups (from 529.27 ± 183.58 to 349.93 ± 221.35 in cases and from 498.87 ± 213.26 to 373.53 ± 215.51 in controls). Variation was greater in the case group (179.33 p= 0.008). Visual acuity increased in both groups. A higher percentage of eyes with improved vision was found in the case group (52.38%). Visual acuity improvement was related to macular thickness recovery.
Conclusions: In cases of cystoid macular edema after cataract surgery with indication of topical treatment with anti-inflammatories, the combination with dorzolamide is effective to reduce macular thickness and improve corrected visual acuity.


REFERENCES

  1. Furtado JM, Lansingh VC, Carter MJ, Milanese MF, Peña BN, Ghersi HA, et al. Causes of blindness and visual impairment in Latin America. Surv Ophthamol. 2013 [acceso: 21/04/2017];57(2):149-77.

  2. Cano M. Perspectiva de prevención de ceguera para el futuro. Rev Salud Ocul Comunit Parag. 2006 [15/11/2020];1(2):3-12. Disponible en: http://www.revistasaludocular.org/diciembre_2006/journal/01_01.html

  3. Río Torres M. Cirugía de cataratas en Cuba. Rev Cubana Oftalmol. 2019;32(1):e710.

  4. Río Torres M, Capote Cabrera A, Hernández Silva JR, Eguias Martínez F, Padilla González CM. Oftalmología. Criterios y tendencias actuales: La Habana: Editorial Ciencias Médicas; 2009.

  5. Conrad -Hengered I, Hengered HF, Schultz T, Burkhard D. Effect of femtosecond laser fragmentation of the nucleus with different softening grid Sizes on effective phaco time in cataract surgery. J Cat Refrac Surg. 2011;38;1888-94.

  6. Río Torres M. Manual de diagnóstico y tratamiento en oftalmología. Sección VI: Retina y Vítreo. La Habana: Editorial Ciencias Médicas; 2009.

  7. Stephen Jae K, Henry J. Prevention of cystoid macular edema after cataract surgery in non-diabetic and diabetic patients: a systematic review and meta-analysis Stephen. Am J Ophthalmol. 2016;161:221-2.

  8. Genead GA. Efficacy of sustained topical dorzolamide therapiy for cystic macular lesions in patients with retinitis pigmentosa and usher syndrome. Arch Opthalmol. 2010;128(9):1146-50.

  9. Lima-Gómez V. Eficacia de la dorzolamida para reducir el grosor retiniano después de la fotocoagulación en el edema macular diabético. Cir Ciruj. 2015;83(1):3-8.

  10. Jigian L, Huigcheng Z. Observación clínica del tratamiento con dorzolamida en EQM poscirugía de catarata. Rev enferm fond ojo Chin. 1997;13(2):89-92.

  11. Shihua J, Wang X. Tratamiento con dorzolamida en el EQM posquirúrgico. China: Rev Oftalmol Clín. 2003;6:554-5.

  12. Ikeda Y, Hisatomi T, Yoshida N, Notomi S, Murakami Y, Enaida H, Ishibashi T. The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa. Graef Arch Clin Exp Ophthalmol. 2012;250(6):809-14.

  13. Ehmann D. Topical timolol-dorzolamide in combination with intravitreal Anti-VEF for retinal vein occlusion macular edema. Philadelphia: Wills Eye Conference; 2017.

  14. American Academy of Ophthalmology. Epidemiology of cataract. AAO; 2016.

  15. Centurión V, Nicoli C, Chávez-Mondragón E. Cristalino de las Américas. La cirugía del cristalino hoy. Panamá: Jaypee-Highlights Medical Publishers, Inc.; 2016.

  16. Chu CJ, Johnston RL, Buscombe C, et al. Risk factors and incidence of macular edema after cataract surgery: a database study of 81 984 eyes. Ophthalmology. 2016;123(2):316-23.

  17. Ramos López M, de Carvalho Bernardo EM, Perera Miniet E, Hernández Ramos H, Hernández Silva JR, Padilla González CM. Tomografía de coherencia óptica de la mácula y de la capa de fibras antes de la cirugía de catarata. Rev Cubana Oftalmol. 2018 [acceso: 29/11/2020];31(1). Disponible en: http://www.revoftalmologia.sld.cu/index.php/oftalmologia/article/view/607

  18. McCafferty S, Harris A, Kew C, Kassm T, Lane L, Levine J, Raven M. Pseudophakic cystoid macular edema prevention and risk factors; prospective study with adjunctive once daily topical nepafenac 0,3 % versus placebo. BMC Ophthalmol. 2017;17(1):16.

  19. Bambo MP, García-Martin E, Otin S, et al. Influence of cataract surgery on repeatability and measurements of spectral domain optical coherence tomography. Br J Ophthalmol 2014;98:52-8.

  20. Lima-Gómez V, Razo-Blanco Hernández DM, García-Rubio YZ. Comparación del cambio del volumen macular entre ojos con y sin mejoría visual después de fotocoagulación en edema macular diabético. Gac Méd Méx. 2014;150:18-23.

  21. Álvarez C, Fromow-Guerra J, Guerrero-Naranjo JL, Quiroz-Mercado H. Correlación entre grosor macular y capacidad visual en pacientes con retinopatía diabética y edema macular clínicamente significativo. Rev Mex Oftalmol; 2004;78(5): 230-6.




2020     |     www.medigraphic.com